Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-506 first-in-human modular phase I-IIa study in advanced solid tumors
NL-OMON51911Phase 1Recruiting
- Sponsor
- Maastricht University
- Start
- Jul 2024
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cp-506 in Nonhematologic neoplasms, ovarian cancer, breast cancer and 4 more (6 arms), sponsored by Maastricht University. Primary endpoints: Safety and tolerability and Dose determination. Started Jul 2024; status: recruiting.
02
Drugs
cp-506
03
Conditions
Nonhematologic neoplasmsovarian cancerbreast cancertriple-negative breast cancer (TNBC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON51911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51911.